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Cardiovascular disease (CVD) is the major cause of mortality in individuals with diabetes mellitus. However the molecular
and cellular mechanisms that predispose individuals with diabetes to the development and progression of atherosclerosis, the
underlying cause of most CVD, are not understood. This paper summarizes the current state of our knowledge of pathways and
mechanisms that may link diabetes and hyperglycemia to atherogenesis. We highlight recent work from our lab, and others’, that
supports a role for ER stress in these processes. The continued investigation of existing pathways, linking hyperglycemia and
diabetes mellitus to atherosclerosis, and the identiﬁcation of novel mechanisms and targets will be important to the development
of new and eﬀective antiatherosclerotic therapies tailored to individuals with diabetes.
1.Introduction
Worldwide, cardiovascular disease (CVD) is the leading
cause of premature death in both men and women. Risk
factors for CVD include abnormal lipid levels, smoking,
hypertension, abdominal obesity, stress, sedentary lifestyle,
and diabetes mellitus [1]. While the incidence of CVD has
declined in many developed countries, this trend is expected
to reverse in the near future [2]. This is largely due to the
dramatic, worldwide increase in the incidence of diabetes
mellitus. Driven by changes in lifestyle and an escalating
rate of obesity, the number of individuals with diabetes may
already be as high as 350 million [3, 4]. Diabetes mellitus is
a major, independent risk factor for cardiovascular disease
(CVD), and individuals with diabetes are 2 to 3 times more
likely to die from CV causes than people with no history of
diabetes, even after controlling for other CV risk factors [5–
9]. These individuals are also at increased risk of diseases
that are associated with CVD and atherosclerosis including
hypertension and renal failure. Ultimately, this translates to a
CV mortality rate in diabetic patients of approximately 75%
[6, 7]. The increasing incidence of diabetes means that the
globalburdenofthis chronicdiseaseonhealthcareresources
will continue to rise for the foreseeable future.
It is not clear why individuals with diabetes are predis-
posed to CVD. Recent reports from clinical trials examining
the eﬀects of intensive blood glucose lowering on CV risk,
including ACCORD (Action to Control Cardiovascular Risk
in Diabetes) [10], ADVANCE (Action in Diabetes and
Vascular Disease: Preterax and Diamicron MR Controlled
Evaluation) [11], UKPDS (United Kingdom Prospective
Diabetes Study) [12], and VADT (Veterans Aﬀairs Diabetes
Trial) [13], suggest that the relationship between hyper-
glycemia and CVD is complex. Despite a vast amount of
research, currently available treatments show only limited
CV beneﬁt and CVD continues to be the major cause of
mortality.
There is a strong correlation between hyperglycemia and
both micro- and macrovascular disease [14–18]. The neg-
ative eﬀects of elevated glucose levels on vascular function
can include decreased proliferation of endothelial cells, the
impairment of some parameters of vascular responsiveness,
and increased endothelial programmed cell death [19–
21]. It is well established that aggressive blood glucose2 Experimental Diabetes Research
lowering signiﬁcantly decreases the incidence and severity
of microvascular disease including retinopathy, renal failure
and peripheral nerve dysfunction [14, 15]. Recent evidence
suggests that increased glycemic control also correlates
with a reduction in macrovascular disease; however, the
relationshipbetweenglucoseloweringandadecreaseinCVD
h a sb e e nm u c hm o r ed i ﬃcult to demonstrate [15]. Several
explanations have been put forth to rationalize the inability
of clinical trials to demonstrate a strong improvement in
cardiovascular outcomes through glycemic control including
the possibilities that the trials were underpowered, were
too short in duration, or were too focused upon fasting
glucose rather than postprandial glucose levels. Alternatively,
these ﬁndings may indicate that the quality of glycemic
control presently achievable is insuﬃcient to be eﬀective
in protecting against macrovascular disease. Therefore, even
short-term deviations in the control of blood glucose may
promote vascular dysfunction.
The pathophysiology of T2D-associated CVD is further
complicated by multiple risk factors, collectively known as
themetabolic syndrome,thatcommonlyaccompanychronic
hyperglycemia. The metabolic syndrome is clinically deﬁned
as a combination of abdominal obesity, insulin resistance
(prediabetes), atherogenic dyslipidemia, and hypertension
[22]. The metabolic syndrome is a major cause of morbidity
and mortality with cardiovascular disease being the primary
clinical outcome [22]. Other complications can include
respiratory diﬃculties, chronic skeletal muscle problems,
gall bladder disease, infertility, hepatic steatosis, circulatory
problems, and certain cancers [23, 24].
Therefore, while a role for hyperglycemia in the devel-
opment and progression of atherosclerosis is supported by
a great deal of basic research, the clinical role of elevated
glucose levels in macrovascular disease is less clear. Fur-
thermore, despite a great deal of research, the mechanisms
that may link high glucose concentrations to the molecu-
lar and cellular pathways of disease development are not
fully understood. This paper will focus on potential direct
proatherogenic consequences of hyperglycemia.
2.MechanismsandPathwaysLinking
DiabetesandHyperglycemiatoCVDand
Accelerated Atherosclerosis
Several mechanisms have been proposed to explain the
proatherogenic eﬀects of diabetes and hyperglycemia. In
general these have focused upon the intracellular eﬀects of
elevated levels of glucose, and the increased availability of
glucose metabolites, in cells of the vascular wall. There is evi-
dence that hyperglycemia is associated with increased aldose
reductase activity that can lead to increased consumption of
NADPH and depletion of GSH levels resulting in elevated
levels of reactive oxygen species (ROS) and subsequent
cellular damage [25, 26]. Glucose-induced PKC activation
has been implicated in decreased endothelial vasodilation
[27] and increased production of ROS [28] that could con-
tribute to endothelial dysfunction. It has also been proposed
that the conversion of sorbitol to 3-deoxyglucosone can
feed into the production of advanced glycation endproducts
(AGEs). AGES are formed through a nonenzymatic process,
known as the Maillard reaction, involving the reaction of
the aldehyde groups of reducing sugars with the amino
groups of proteins [29, 30]. There are several potential
pathways where AGE-modiﬁed proteins could be damaging;
the formation of AGEs may alter protein function [31],
disrupt the extracellular matrix [31, 32], and/or lead to
the modiﬁcation of lipoprotein particles thereby increasing
their atherogenicity. However the predominant vascular
eﬀect of AGEs appears to occur through their interaction
with RAGE (receptor for AGE) found on macrophages and
endothelial and smooth muscle cells [33–35]. The AGE-
RAGE interaction triggers a signal transduction cascade that
resultsintheproductionofintracellularROSthatcaninitiate
an inﬂammatory response [36, 37].
While preclinical evidence supports a causative role for
oxidativestressinatherogenesis[38–41],virtuallyeverywell-
controlled clinical trial has failed to show a cardiovascular
beneﬁt in diabetic patients receiving antioxidant supple-
ments [42–46]. There are several ways to rationalize this
apparent paradox by questioning: the speciﬁc antioxidants
tested, the doses prescribed, and/or the power and duration
of the trials themselves. However, these clinical observations
may be indicative of the existence of other important
molecular mechanisms or pathways that play a causative role
in diabetic atherogenesis in addition to oxidative stress.
2.1. The Hexosamine Pathway. Conditions of hyperglycemia
also result in the shunting of excess intracellular glucose
through the hexosamine biosynthetic pathway (HBP). In a
typical cell, under normoglycemic conditions, 1 to 3% of
total glucose will be converted to glucosamine-6 phosphate
by the enzyme glutamine:fructose-6 phosphate amidotrans-
ferase (GFAT) [47]. When intracellular glucose levels rise,
ﬂux through this pathway increases. Furthermore, increased
G F A Te x p r e s s i o na n da c t i v i t yh a v eb e e nr e p o r t e di nt i s s u e s
fromhumanswithdiabetes [48].Thenetresultisanelevated
intracellular concentration of glucosamine. This eﬀect has
been observed in cultured cells challenged with elevated
concentrations of glucose as well as in vascular and hepatic
tissues of hyperglycemic animals [49–52].
Increased hexosamine pathway ﬂux has been impli-
cated in several diabetes-associated complications including
insulin resistance [47, 53] and pancreatic β cell death [54], as
well as atherosclerosis [55]. The molecule mechanisms that
underlie the pathogenic eﬀects of increased HBP ﬂux are
not fully understood. Most research has focused upon the
role of UDP-N-acetylglucosamine (UDP-GlcNAc), the end-
product of the HBP pathway and a substrate for both O- and
N - l i n k e dp r o t e i ng l y c a t i o n ,a sac a u s a t i v ea g e n t .I ti sw e l l
established that elevated glucosamine concentrations drive
the O-linked glycosylation of proteins including transcrip-
tion factors [56] and nuclear pore proteins [57], as well as
signaling factors [58] which potentially alters their function,
stability, and/or activity. Speciﬁcally, studies have suggested
that O-glycosylation may regulate transcription, plasma
lipids, and gluconeogenesis by modulating the activationExperimental Diabetes Research 3
o fR N Ap o l y m e r a s eI I[ 59], angiopoietin-like protein 3
[60], FoxO1, and CRTC2 [61, 62], respectively (further
reviewed in [63]). Glucosamine has been shown to desen-
sitize insulin-stimulated glucose uptake in both adipocytes
[47] and skeletal muscle cells [64], probably by inhibiting
the translocation of the glucose transporter, GLUT4, to the
cell surface [65]. In addition, increased hexosamine pathway
activity can promote the transcription of proinﬂammatory
and prothrombotic factors including TGF-α,T G F - β,a n d
PAI-1 [66–68]. Therefore, the hyperglycemia-induced O-
GlcNAc modiﬁcation of proteins may change gene expres-
sion patterns and alter the function of speciﬁc factors that
contribute to a proatherogenic, prothrombophilic vascular
environment. More studies are required to test this theory
and to precisely determine the factors and downstream
pathways that may be involved in the acceleration of vascular
disease.
UDP-GlcNAc is also a substrate for N-linked protein
glycation that occurs in the endoplasmic reticulum (ER). N-
glycosylation is an important posttranslational modiﬁcation
of nascent proteins that is critical for proper protein folding
[69]. Mutations in asparagine residues of speciﬁc proteins,
which are critical for N-glycosylation, result in disrupted
folding, secretion and/or activity [70–72]. Tunicamycin, a
UDP-GlcNAc antagonist, has been shown to inhibit N-
glycosylation and activate the cell’s quality control mech-
anism: the unfolded protein response [73–75]. Ultimately,
disruptions in the N-glycation process can lead to an
accumulation of unfolded/misfolded proteins in the ER that
perturb the ER homeostatic balance; this is known as “ER
stress.” An additional intracellular eﬀect of glucosamine,
which has not been investigated in the context of diabetes
andatherosclerosis,isitsabilitytopromotetheaccumulation
of unfolded proteins in the ER, thereby leading to ER
dysfunction and cell injury [75–78].
3.The Endoplasmic Reticulumand
the Unfolded ProteinResponse
In a typical eukaryotic cell, the ER is responsible for the
proper modifying, folding, and traﬃcking of approximately
one-third of all proteins. ER-localized modiﬁcations of
nascent proteins include disulﬁde bond formation and N-
linked glycosylation, which are critical to protein folding
[69]. Unfolded/misfolded proteins are directed to undergo
ER-associated degradation (ERAD), and, under physiologi-
cal conditions, the ER is able to maintain a homeostatic bal-
ance between folded and misfolded proteins [79]. When the
ER processing capacity is overwhelmed, unfolded/misfolded
proteinsaccumulateanddisrupttheERhomeostaticbalance;
this is known as ER stress.
Traditional ER-stress-inducing agents are known to
disrupt protein folding by interfering with disulphide bond
formation (dithiothreitol) [80], ER Ca2+ balance (A23187,
thapsigargin) [81], ER membrane structure (palmitate,
unesteriﬁed cholesterol) [82, 83] or by blocking protein N-
glycosylation (tunicamycin) [84]. Conditions of ER stress
activate the unfolded protein response (UPR) which func-
tions to restore ER homeostasis (Figure 1). The UPR is a
three pronged signaling cascade that is initiated by trans-
membrane ER proteins known as inositol-requiring enzyme
(IRE)-1, activating transcription factor (ATF)-6, and PKR-
like ER kinase (PERK) [85]. Initiation of these pathways
alleviates ER stress by decreasing protein synthesis, increas-
ing ER chaperone levels, and facilitating degradation of
irreversibly misfolded proteins. Under conditions of chronic
ER stress, upregulation of pathways involved in lipid accu-
mulation (SREBP) and inﬂammation (NF-κB) can occur
[49, 86–88]. If the UPR is unable to restore ER homeostasis,
proapoptotic signaling factors (i.e., GADD153/CHOP) are
upregulated to initiate programmed cell death [89].
3.1. ER Stress and Atherogenesis. There is increasing exper-
imental evidence in support of a direct and causative role
for ER stress in the development and/or progression of
atherosclerosis. First, several independent risk factors for
CVD, including hyperglycemia [49], hyperhomocysteinemia
[7, 88], obesity [90], and elevated levels of palmitate [91]
and unesteriﬁed cholesterol [92], have been associated with
ER stress, suggesting that this pathway may represent a
common or unifying mechanism of accelerated atheroge-
nesis [93, 94]. Secondly, activation of the UPR has been
noted at all stages of atherosclerotic development, from a
fatty streak to an advanced occlusive plaque [95]. Third,
conditions of ER stress can activate/dysregulate metabolic
pathways that are directly involved in the development of
atherosclerotic lesions. ER-stress-inducing agents promote
lipid accumulation by activating the sterol regulatory ele-
ment binding proteins (SREBPs), which are transcription
factors that control lipid biosynthesis and uptake [88, 96,
97]. ER-stress-inducing agents also activate NF-κB, the
transcriptionfactorresponsibleforpromotinginﬂammatory
gene expression [98, 99]. Finally, ER stress has been shown
to activate caspases and promote apoptosis of human aortic
endothelial cells and other cell types [100, 101]. Together,
lipid accumulation, inﬂammation, and endothelial apoptosis
are the hallmark features of atherosclerosis [102, 103].
3.2. Glucosamine-Induced ER Stress. Our lab has recently
overexpressed the HBP rate limiting enzyme, GFAT, using an
adenoviral expression system in cell culture and measured a
signiﬁcant increase in UPR gene expression and downstream
eﬀects of ER stress including lipid accumulation, inﬂam-
matory gene expression, and apoptotic signaling under
hyperglycemic conditions [86]. We have shown that addition
ofexogenousglucosamine,orincreasedendogenousproduc-
tion of glucosamine, can disrupt the capacity of the ER to
process nascent proteins and initiate an ER stress response.
Furthermore, this eﬀect has been observed in cell types that
are relevant to the development of atherosclerosis, includ-
ing human aortic smooth muscle cells, monocyte-derived
macrophages, and HepG2 cells [49, 50, 100, 101]. Thus,
elevated levels of glucosamine may play an important role
in ER and cellular dysfunction associated with atherogenesis.
It is not known how increased concentrations of glu-
cosamine (but not mannose) disrupt protein folding in4 Experimental Diabetes Research
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Figure 1: The unfolded protein response to endoplasmic reticulum stress. ER stress occurs when the capacity of the ER to process/fold
proteins is exceeded by the load of nascent proteins entering the ER. The function of the UPR is to reestablish ER homeostasis by decreasing
protein ﬂux into the ER (translation block) while increasing the folding capacity of the ER (increased chaperone expression). Conditions of
ER stress lead to the dissociation of ER chaperone GRP78 from the trans-ER-membrane signaling factors PERK, IRE1, and ATF6, resulting
in their activation. Activated PERK phosphorylates and inhibits the activity of eIF2α, an essential factor in general protein translation.
PERK is also involved with the downstream activation of transcription factors including ATF4 and GADD153. Activated IRE1 assists in the
alternative splicing of XBP-1 resulting in the translation of a transcription factor, XBP-1, which is involved in upregulation of the expression
of ER chaperones. Activated ATF6 translocates to the Golgi where proteases S1P and S2P release an N-terminal transcription activation
domain that works in concert with XBP-1 to upregulate ER chaperone expression.
the ER. UDP-N-acetylglucosamine is an essential substrate
for both O- and N-linked protein glycosylation, and protein
glycosylation is an important step in the proper folding of
many proteins [69]. It is known that elevated concentrations
of glucosamine increase levels of O-linked protein glycosyla-
tion [49] and alter N-linked glycosylation patterns of speciﬁc
proteins including ApoB100 [104]. It is possible that either
of these eﬀects could promote ER stress. In cultured HepG2
cells, our lab has shown that PUGNAc, an inhibitor of O-
GlcNAcase, increases protein-O-GlcNAc levels but does not
p r o m o t eE Rs t r e s s[ 49]. This may suggest that glucosamine-
induced ER stress is caused by free and not protein O-
linked glucosamine. We hypothesize that increased levels of
glucosamine, or a derivative of glucosamine, may interfere
with a step in the N-linked glycation of proteins resulting in
the production of misfolded proteins and the activation of
the UPR.
Elevated levels of glucosamine and glucosamine-induced
ER stress have been previously implicated in acquired
insulin resistance [47, 53, 105, 106]; however, there is
some controversy to whether this eﬀect is physiologically
relevant in humans. Incubation of relatively high concen-
trations of glucosamine (1–10mmol/L) in adipose, muscle,
or endothelial cell cultures has been implicated in impaired
insulin action [106–109]. Furthermore, high levels of intra-
venously injected glucosamine (plasma concentrations of
0.5–1.8mmol/L) in both animals and humans have also
been shown to cause insulin resistance [110, 111]. The
recommended daily dose of oral glucosamine supplements,
commonly taken to treat joint pain, are far lower (plasma
concentrations of ∼3μmol/L), and data suggest that these
s u p p l e m e n t sh a v en oe ﬀect on insulin sensitivity [112, 113].
Additionalstudieswillberequiredtodeterminetheeﬀectsof
chronic hyperglycemia on endogenous, intracellular levels of
glucosamine and possible eﬀects on insulin resistance.
4.Hyperglycemia,ERStress,and
Accelerated Atherosclerosis
To investigate the molecular mechanisms that link hyper-
glycemia to atherosclerosis, we have established a model
in which we inject ApoE−/− mice with multiple low
doses of streptozotocin (STZ) [49, 50, 114]. Using this
model we have observed a correlation between hyper-
glycemia, the accumulation of glucosamine in the artery
wall, vascular ER stress, and accelerated atherogenesis [49]
(Figure 2). Signiﬁcantly, ER stress levels in the endothelium
of hyperglycemic mice increase prior to the development of
the atherosclerotic lesions, a result that is consistent with ER
stress playing a causative role in lesion development [50]. In
addition, accelerated lesion development is observed in these
diabetic mice before the onset of dyslipidemia, suggesting
that hyperglycemia is suﬃcient to independently promote
the activation of proatherogenic processes [49].
In a direct test of the atherogenic potential of glu-
cosamine, we have recently found that ApoE−/− mice given
drinking watercontaining 5%glucosamine (w/v)for7weeks
have signiﬁcantly increased vascular and hepatic ER stress
levels in addition to larger atherosclerotic lesions than mice
given regular water or water containing 5% mannitol (w/v)
[115]. This is consistent with a report from Tannock et al.
who found that 5 weeks of glucosamine supplementation
increased lesion size in LDL-receptor-deﬁcient mice [116].Experimental Diabetes Research 5
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Figure 2: Analysis of aortic root from normoglycemic, STZ-injected hyperglycemic, and STZ-injected insulin-treated ApoE−/− mice.
HyperglycemicmiceshowincreasedvascularO-linkedGlcNAc,elevatedlevelsofERstressmarkers(GRP78/94),andsigniﬁcantlyaccelerated
atherosclerotic lesion development, relative to normoglycemic controls. Normalization of glucose levels with insulin attenuates O-GlcNAc
accumulation, ER stress, and atherogenesis.
Our data suggests that glucosamine-induced ER stress plays
a direct and causative role in accelerated atherogenesis.
5. ERStress in Patientswith
MetabolicSyndrome
There is ample evidence in vitro and in animal models
to support a role for ER stress in the development and
complications of diabetes. Recently, small clinically relevant
studies involving humans with metabolic syndrome have
been carried out. Patients with diabetic nephropathy have
beenshowntohaveincreasedGFATexpressioninglomerular
epithelial and mesangial cells and that GFAT is expressed in
most tissues involved in diabetic complications [48, 117].
Pancreatic beta cells isolated from type 2 diabetics have
been shown to have marked expression of ER stress markers
[118] and increased susceptibility to ER stress compared to
nondiabetic controls[119]andthatERstressmaycontribute
to IL-1β production, mild islet inﬂammation [120], and β-
cell failure [118]. Our lab has recently shown that isolated
leukocytes from human subjects with metabolic syndrome,
compared to healthy subjects, have elevated levels of ER
stress markers and that there is an association between acute
and chronic dysglycemia and ER stress in humans [86].
Each of these trials is consistent with diabetes-associated ER
stress playing a clinically relevant role in the pathogenesis of
diabetic complications.
6. Targets for Potential
Therapeutic Intervention
The identiﬁcation of a role for ER stress and/or the UPR
in the development and progression of diabetes-associated
atherosclerosis is signiﬁcant, not only because it gives us
insight on an important disease process, but also because it
illuminates novel potential targets for therapeutic interven-
tion (Figure 3). Eﬀorts to develop strategies to manipulate
the UPR have already begun, especially with respect to other
diseases and disorders in which ER stress is thought to play
a role. At least three general approaches have been used to
address this problem. The ﬁrst involves reducing the levels of
ER stress directly by relieving the load of misfolded proteins
though the addition of chemical chaperones such as 4-
phenylbutyric acid (4-PBA), taurine-conjugated ursodeoxy-
cholic acid (TUDCA), or dimethyl sulfoxide (DMSO) [121–
123]. The mechanisms by which these small molecules
function to reduce ER stress levels are not well deﬁned.
However, such strategies have been shown to be eﬀective6 Experimental Diabetes Research
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Figure 3: Working model of diabetes-associated accelerated atherothrombosis. Chronic hyperglycemia leads to increased ﬂux through the
hexosamine biosynthesis pathway (HBP) resulting in accumulation of UDP-N-acetylglucosamine (UDP-GlcNAc), a substrate for both O-
and N-linked protein glycosylation, as well as increased levels of ER stress. Disruptions in ER homeostasis lead to activation of the unfolded
protein response (UPR) and downstream eﬀects including activation of glycogen synthase kinase (GSK)-3. Our results suggest that ER-
stress-induced GSK-3 induces proatherogenic processes leading to the accelerated development of atherothrombosis.
invitroandinvivo,and4-phenylbutyricacidhasbeenshown
to attenuate atherosclerosis in an ApoE−/− mouse model
[124] .As e c o n ds t r a t e g yi st oa u g m e n tt h ep r o t e c t i v ea s p e c t s
of the endogenous UPR. This has previously been accom-
plished through the over-expression of ER-resident protein
chaperones including GRP78. The third approach is to target
some of the detrimental downstream eﬀects of ER stress.
Examples of this strategy include the use of salubrinal which
inhibits the phosphatase GADD34 from reactivating eIF2α,
thereby maintaining the PERK pathway-induced translation
block (Figure 1). Other possible targets for intervention
would include proinﬂammatory and/or proapoptotic factors
such as ASK1, p38MAPK, or GADD153/CHOP. Indeed,
GADD153/CHOP-deﬁcient mice are resistant to acceler-
ated atherosclerosis [125, 126]. Recently we have identiﬁed
glutamine:fructose-6-phosphate amidotransferase (GFAT)
and glycogen synthase kinase (GSK)-3 as two enzymes
involved in ER stress and potential targets for therapeutic
intervention.
6.1. Glutamine:Fructose-6-phosphate Amidotransferase
(GFAT). The potential role of glucosamine-induced ER
stress in diabetic atherogenesis highlights the importance of
glutamine:fructose-6-phosphate amidotransferase (GFAT),
the rate-limiting enzyme in the conversion of glucose
to glucosamine, also known as the hexosamine pathway
[127, 128]. A central role for GFAT activity in the ER stress
pathway is supported by our ﬁnding that inhibition of
GFAT attenuates glucose-induced ER stress [49] and that
overexpression of GFAT is suﬃcient to promote ER stress
in HepG2 cells cultured in normoglycemic conditions [86].
We are currently developing strategies to modulate GFAT
activity in vitro and in our mouse models. These tools will be
used to investigate the potential eﬀects of regulating GFAT
activity on the UPR and on activation of proatherogenic
processes.
6.2. Glycogen Synthase Kinase (GSK)-3. The mechanisms
that link conditions of ER stress to the activation of
proatherogenic pathways are not known. GSK-3α and β are
two homologous serine/threonine kinases that are involved
inadiversenumberofintracellularsignalingpathways[129].
We have shown using small molecule inhibitors and GSK-
3α−/− and GSK-3β−/− mouse embryonic ﬁbroblasts that
GSK-3-deﬁciency attenuates ER-stress-induced apoptosis
and lipid accumulation [114, 130–132].I nv i v owe have
shownthathyperglycemicmicefedadietsupplementedwith
valproate, a compound that inhibits GSK-3 activity, have
reducedhepatic GSK-3activityandreducedlesionvolume at
the aortic sinus [114]. Together, the above ﬁndings support
our hypothesis that glucosamine-induced ER stress plays a
role in accelerated atherogenesis and identiﬁes GSK-3 as a
potential target for antiatherogenic therapy. The limitation
of targeting GSK-3 arises from the central role that this
kinase plays in many diverse metabolic processes and the
possibility of detrimental side-eﬀects of small molecular
inhibitors [118].
7. Conclusions
Because of the cardiovascular risks of diabetes and the
increasing prevalence of type 2 diabetes, it is essential
that we further our knowledge of how and why diabetes
mellitus and hyperglycemia promote cardiovascular disease.Experimental Diabetes Research 7
Currently, and for the near future, the primary strategy for
managing cardiovascular disease in the diabetic population
willbethroughthecontrolofhyperglycemiaandthroughthe
treatment of associated complications such as hypertension
and dyslipidemia using established medications such as ACE
inhibitors, statins, and ﬁbrates.
The continued identiﬁcation and investigation of path-
ways linking hyperglycemia and diabetes mellitus to
atherosclerosis is important to the development of new and
eﬀective antiatherosclerotic therapies that are tailored to
individuals with diabetes. A great deal of research has been
focused upon the role of hyperglycemia in the development
and progression of atherosclerosis in cell culture and animal
model systems. Several mechanisms have been identiﬁed
that appear to link glucose to proatherogenic processes. The
most promising of these, the polyol pathway, PKC activation,
the hexosamine pathway, and the AGE-RAGE interaction,
show potential and are actively being evaluated as targets
for putative antiatherogenic therapies. Thus far, however, all
interventions targeting the eﬀects of hyperglycemia, includ-
ing direct glucose lowering, appear to show greater eﬀect in
the treatment of microvascular complications than in the
control of macrovascular disease. This is likely due, at least
in part, to the complexities of atherosclerosis and current
limitations of the animal models available to researchers who
study the development and progression of atherosclerosis.
Additional studies are obviously required to further our
understanding of this important disease.
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